跳至主要内容
临床试验/EUCTR2010-020204-30-GB
EUCTR2010-020204-30-GB进行中(未招募)1 期

A Multicenter, Open-label, Sequential, Multiple-dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Efficacy or Eritoran in Descending Age Groups of Pediatric Subjects with Severe Sepsis

Eisai Limited0 个研究点目标入组 45 人开始时间: 2010年10月6日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Eisai Limited
入组人数
45

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • - Male and female subjects, age from gestational age greater than or equal to 38 weeks to less than 18 years with confirmed early-onset sepsis, as defined in the protocol
  • - Must be a reasonable likelihood that the study drug adminstration can begin within 24 hours of the onset of sepsis-induced cardiovascular or respiratory organ dysfunction, whichever occurs first
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Subjects with either sepsis-induced cardiovascular or respiratory organ dysfunction for greater than 24 hours before likely start time of study drug administration
  • - Subjects who experienced an episode of sepsis-induced organ dysfunction (cardiovascular or respiratory) within the prior 45 days
  • - Subjects whose death appears imminent

研究者

发起方
Eisai Limited

相似试验

进行中(未招募)
1 期
A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.
EUCTR2014-004693-42-GBIntercept Pharmaceuticals, Inc.72
进行中(未招募)
1 期
A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body.Biliary atresiaMedDRA version: 20.0Level: LLTClassification code 10004653Term: Biliary atresiaSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10004654Term: Biliary atresia, congenitalSystem Organ Class: 100000004850
EUCTR2014-004693-42-FIIntercept Pharmaceuticals, Inc.72
进行中(未招募)
1 期
A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.
EUCTR2014-004693-42-ITINTERCEPT PHARMACEUTICALS INC.32
进行中(未招募)
1 期
A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.Biliary atresiaMedDRA version: 20.0Level: LLTClassification code 10004653Term: Biliary atresiaSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10004654Term: Biliary atresia, congenitalSystem Organ Class: 100000004850
EUCTR2014-004693-42-FRIntercept Pharmaceuticals, Inc.32
进行中(未招募)
1 期
A study to look at how the study drug Obeticholic Acid (OCA), when given as a single dose and multiple doses, is tolerated in children who have biliary atresia and to look at the effects that the study drug has on the body including an optional long-term extension.Biliary atresiaMedDRA version: 20.0Level: LLTClassification code 10004653Term: Biliary atresiaSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10004654Term: Biliary atresia, congenitalSystem Organ Class: 100000004850
EUCTR2014-004693-42-DEIntercept Pharmaceuticals, Inc.8